Home / News / TissueGen appoints Edward Parent as director

TissueGen appoints Edward Parent as director

30 Sep '17

2 min read

TissueGen, developer of Elute fibre, a groundbreaking biodegradable fibre format for advanced drug delivery, has appointed Edward Parent as director, Quality Assurance to guide clinical application and commercial scale-up of its core technology. Ed most recently served as scientist at Evonik Industries, where he advised and implemented technology transfer.

Parent has over 35 years of experience in a broad range of FDA regulated environments and guiding compliance with GMP requirements and various quality management systems.

Parent’s diverse career has included positions with start-up companies like Biomatrix and Hylamed / LuroMed and large corporations such as Johnson & Johnson and Genzyme Biosurgery in roles including director of technical operations, principal scientist, and quality engineer. He has been responsible for advancing multiple early stage products from concept to clinical trial and commercialisation. Prior to joining TissueGen, Ed served as a scientist at Evonik Industries, where he advised and implemented technology transfer, scale up, and new product development of biodegradable polymers.

“We see a tremendous opportunity for Elute fibre to redefine the way drug delivery, tissue engineering and nerve regeneration are approached. The combination of biotech, medical device and pharmaceutical industry expertise that Parent brings to TissueGen will accelerate our path towards clinical application and scale up commercialisation of Elute fibre-based products,” said Christopher Knowles, president and CEO of TissueGen.

TissueGen’s Elute fibre can directly replace standard fibres in biodegradable medical textiles and may significantly improve clinical outcomes by delivering therapeutic agents directly at the surgical site. Through localised delivery of drugs at the site of implantation, Elute fibres may orchestrate the body’s healing and regenerative processes.

“Elute fibre has the potential to play a pivotal role in the next-generation of medical devices and I am eager to apply the skills I’ve honed throughout my career to guide the company towards clinical application and large-scale commercialisation.” said Parent.

Parent is a member of the Society for Biomaterials, Controlled Release Society and American Society for Quality. He is also a published author and holds four patents. (SV)

Fibre2Fashion News Desk – India